Friday, February 23, 2018

India Cold Chain Market Outlook to 2022: Ken Research

The report titled “India Cold Chain Market Outlook to 2022 - by Cold Storage & Cold Transport, 3PL, End User Industry (Agro food, Fruits & Vegetables, Fruit pulp & Concentrates, Dairy Products, Ice Cream, Meat, Sea Food, Confectionery, Poultry, Ready to Cook, Pharmaceutical, Industrial Products)” provides information on market size for India cold chain, cold storage and cold transport. The report covers aspects such as cold chain market segment (by cold storage and cold transport, by type of products), cold storage market segment (by organized and unorganized, by size of firms, by products, by domestic and international cold storage, by region and by owned and rented cold storage), cold transport market segment (by organized and unorganized, by domestic and international cold chain transport, by mode of transport and by domestic and international cold chain companies), competitive landscape of major players in India cold chain market and covering competitive landscape of major cold chain companies including Snowman Logistics, Cold Star Logistics, Schedulers, Gubba Cold Storage, Kailash Agro Cold Storage, M J Logistics Services, Deccan Cold Storage Pvt Ltd, Dev Bhumi Cold Chain, Gati Kausar Cold Chain Solutions and ColdEx Pvt. Ltd. The report concludes with market projection for future and analyst recommendations highlighting the major opportunities and cautions.
India Cold Chain Market Overview
The cold chain industry in India remains underserved and presents huge potential in terms of expansion. As of 2014, there exists a requirement of 3.3 million MT of cold storage and 52.7 thousand reefer trucks. The market revenue increased from INR ~ billion in 2012 to INR ~ billion in 2017 at a CAGR of ~%. The total cold storage capacity is estimated at ~ million MT with ~cold storages and ~ reefer trucks operating in the space as of 2017.
The market can be largely segmented into cold storage and cold transportation. The cold storage segment held the major share of the market and was about ~% of the total cold chain market in terms of total market revenue in 2017. The cold transportation industry contributed around ~% of the total revenue in 2017.
Agricultural products such as fruits, vegetables, fruit pulp, concentrates and others have accounted for the highest share of ~% of the revenue share in India Cold Chain Market in 2017. This is followed by meat and poultry with ~%, dairy products market with ~%, ice cream market with ~%, and seafood industry with ~%. Confectionery and ready to cook products have together accounted for ~% of the cold chain revenue and pharmaceutical and industrial products have captured a smaller share of ~% in 2017.
India Cold Storage Market
Overview: India cold storage market increased from INR ~ billion in 2012 to INR ~ billion in 2017 at a CAGR of ~%. The country is dominated by a large number of small and medium sized cold storage units located near farms, seaports, airports, pharmaceutical hubs and food processing clusters
Segmentation: India cold storage market is dominated by a large number of small unorganized firms which have accounted for ~% of the overall revenue of cold storage market in 2017 whereas the organized players have gathered ~% of the market in 2017.
Small warehouses with a capacity of less than 1,000 pallets have accounted for ~% of the cold storages in India in FY’2017. The medium sized cold storages with a pallet size of 1,000 to 5,000 have captured ~% of the market and the large scold storages have gathered ~%.
Further, the market is dominated by domestic cold storage companies with ~% of the total cold storages in India in FY’2017 and the international companies have captured the rest ~% of the cold storages.
Future Potential: With the shift in focus from increasing the production to better storage and transportation facility of the commodity, the cold storage market in India is projected to reach INR ~ billion by 2022 at a CAGR of ~% during 2017 to 2022.
India Cold Transport Market
Overview:  India cold storage is in the growth stage with ~ reefer trucks as of 2017 dominated by small and non integrated firms. The cold transport market increased from INR ~ crore in 2012 to INR ~ crore in 2017 at a CAGR of ~%. Furthermore, the fleet size increased from ~ in 2012 to ~ in 2017.
Segmentation: The unorganized sector has accounted for ~% of the revenue share in India cold transport market in 2017. The share of organized sector has increased from ~% in 2012 to ~% in 2017.
Road and rail freight has accounted for ~% of the revenue in India cold transport market in 2017. This is driven by growth of online grocery, food processing industry and improving road infrastructure. Air freight transport has gathered ~% of the market revenue in 2017. Highly temperature sensitive goods such as pharmaceutical products majorly use air transport. Sea transport has captured a minor share of ~% in the total revenue of India cold transport market in 2017. The major driving factor is the rise in trading activities in the country.
Future Potential:  India cold transport market is expected to increase from INR ~ crore in 2017 to INR ~ crore in 2022 at a CAGR of ~%. The cold transport market will be majorly driven by rise in trading activities involving perishable and time sensitive products.
Competitive Scenario in India Cold Chain Market
India cold chain market is in the growing stage with major players undertaking expansion strategy to tap the huge potential present in sector. The companies compete on various parameters including the warehouse capacity, number of pallets, fleet, temperature range, network coverage and locations. In future, the market is expected to consolidate.
The major players in India cold chain market include Snowman Logistics, Cold Star Logistics, Schedulers, Gubba Cold Storage, Kailash Agro Cold Storage, M J Logistics Services Ltd, Deccan Cold Storage Pvt Ltd, Dev Bhumi Cold Chain, Gati Kausar Cold Chain Solutions and ColdEx Pvt. Ltd
India 3pl Cold Chain Market 
India 3PL cold chain market increased from INR ~ billion in 2012 to INR ~ billion in 2017 at a CAGR of ~%. India 3PL cold chain market is in the nascent stage majorly driven by entry and expansion of local and international QSR chains, supermarket chains such as Reliance Fresh, Safal, EasyDay and others. Further, the growth of online grocery stores such as BigBasket, Grofers and others has further facilitated the 3PL cold chain market. With the constant shift in client business, more customized and value-added services are required along with standardized services offerings. In order to widen their network coverage, large cold chain companies have tied up with local 3PL service providers in order to better serve the local markets
Future Potential of India Cold Chain Market
The market is expected to reach INR ~ billion by 2022 at a CAGR of ~% during 2017 to 2022. The market will be driven by technological advancements and rising share of organized players in the market. The growth of online grocery retail and food processing industry will further create demand for cold storage and transportation facilities as major players and QSR chains undertake expansion across various cities in the country. The government will launch new scheme called SAMPADA for development of small and medium scale processing clusters close to the growing areas of the specific farm produce. Cold chain companies further plan to upgrade their facilities to offer multipurpose cold storage services.
Key Topics Covered in the Report:
India Cold Chain Market
Temperature Controlled Logistics Market India
Cold Storage Capacity India
Number of Reefer Trucks India
Number of Cold Storages India
Cold Warehouse Market India
Organized Cold Storage Sector India
Multi-Purpose Cold Storage Industry India
Cold Distribution Market India
Major Companies in Cold Chain Industry
Value Chain Cold Chain India
Cold Chain Logistics Infrastructure India
India Cold Chain Demand Supply Gap
Size of Cold Storages India
Potato Storage India
Investment Cold Storage Facility India
India 3PL Cold Chain Market
India 3PL Cold Transport Market
India 3PL Cold Storage Market
Cold Chain Projects India
Uttar Pradesh Cold Chain Market
Gujarat Cold Chain Market
West Bengal Cold Chain Market
Assam Cold Chain Market
Odisha Cold Chain Market
Tamil Nadu Cold Chain Market
Jammu and Kashmir Cold Chain Market
India Cold Chain Future Outlook
India Cold Chain Competition
India’s Cold Chain
Comparative Analysis India Cold Chain
India Cold Chain Challenges
SWOT India Cold Chain
Temperature Controlled Logistics Services Market in India
Cold Chain Logistics India
India Cold Chain Future Outlook
Subsidy Scheme for India Cold Chain
Cold Transport Fleet Size India
For more information on the research report, refer to below link:
Related Reports by Ken Research
Contact:         
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-124-4230204

Thursday, February 22, 2018

Indonesia Pharmaceutical Market will be led by Growing Generic Drugs and Bio-pharmaceutical Market: Ken Research

Expansion of product portfolio by major pharmaceutical companies and increase in demand for generic drugs were the key factors driving growth in Indonesia pharmaceutical Market.
Indonesia healthcare market has observed a favorable growth in the last 5 years. The market is still under penetrated especially in the tier 2 areas in Indonesia as of 2017.
The launch and execution of JKN scheme by the government has led to surge in demand for primary healthcare facilities and increased generic drug sale. The market has underscored various deregulation programs which has stimulated foreign investment in the industry.
Indonesia Pharmaceutical market is dominated by domestic players which controlled majority of the market in 2017. Recent favorable government regulations have facilitated the entry of foreign players in the space. There are 206 pharmaceutical companies (182 domestic and 24 international companies) located in Indonesia.
The market is driven by deregulation in FDI regulations in pharmaceutical and favorable government policies leading to increase in sale of generic drugs. Increased investment in innovation of new drugs with higher margin led to increased profitability of pharmaceutical companies. Expansion of major companies through mergers, acquisitions and alliances has enabled companies to manufacture high end medicines and pharmaceutical products.
The local companies largely focus on generic drugs manufacturing that are dependent on imported active pharmaceutical ingredients (API), mainly from China and India.
As Jaminan Kesehatan Nasional (JKN) has prioritized the use of generic drugs, the demand for unbranded generic drugs has grown as Indonesians increasingly rely on generic drugs. This has augmented the domestic players’ sales. But at the same time, the market has also witnessed an increase in number of new players which has driven down the margins.  Since the product portfolio of majority domestic pharmaceutical companies is dominated by generic drugs, the sales have gone up since 2014. Moreover, the prices of generic drugs are regulated and consistent across Indonesia whereas the prices increase by 10% for branded drugs annually. Domestic players have witnessed success in rural areas of Indonesia. Due to inaccessibility and language barrier existing in the rural areas, the domestic players have been better able to bridge the gap as compared to international players.  The domestic players have also dominated the Over the Counter drugs which are driven by the increasing self medication behavior of the population. Domestic players dominate the Anti-Infectives, Gastrointestinal and metabolism and respiratory therapeutic segments.
Indonesia biopharmaceutical industry is in the nascent stage. There is a strong interest from research-based global biopharma companies to conduct clinical research in Indonesia because of the large concentrated patient populations and disease profiles. Furthermore, as the industry intends to move towards self sufficiency, Indonesian government released the 11th economic stimulus package with the aim of boosting the domestic production of medicines' raw materials, particularly for five product categories namely biotechnology, vaccines, herbal extracts, active pharmaceutical ingredients and medical devices.
In order to tap the existing potential, large domestic pharmaceutical companies have tied up with international players to manufacture biopharmaceutical products for the treatment of chronic diseases such as cancer, kidney failure and others
ProBioGen AG, a CDMO based in Germany, and Bio Farma, a state-owned vaccine manufacturer in Indonesia, has signed an agreement to develop a biosimilar to the monoclonal antibody (mAb) trastuzumab for cancer treatment that will be produced in Indonesia.
Kalbe Farma has also launched biosimilar version of insulin in Indonesia to treat diabetes mellitus which is 38% cheaper than the existing insulin. Biosimilars are cheaper imitations of drugs known as biologics.
Kalbe Farma set up its biological drug factory, PT Kalbio Global Medika in Cikarang, Bekasi, with an investment value that ranges between USD 30 to USD 35 million. The factory is built under the joint venture between Kalbe and a South Korean pharmaceutical company Genexine Inc, PT Kalbe-Genexine Biologics
Key Topics Covered in the Report:
Indonesia Dietary Vitamin Supplements Market
Pharmaceutical Market Size Indonesia
Indonesia Vaccine Market
Indonesia Pharmaceutical Regulations
Number of Pharmaceutical Companies Indonesia
Indonesia Pharmaceutical Market Players
Obese Population Indonesia
Generic Drug Market Size Indonesia
Number of Healthcare Centers in Indonesia
Budget Allocation on Healthcare Indonesia
Healthcare Spending Indonesia
Vitamin and Dietary Supplement Market Indonesia
For more information on the research report, refer to below link:
Related Reports by Ken Research
Contact:         
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-124-4230204

Genetic disorders market is forecast to grow at 13.6% CAGR: Ken Research


Genetic disorders market is forecast to grow from $19.6 billion in 2016 to $47.7 billion in 2023, at a CAGR of 13.6%. This high level of growth will be driven largely by orphan drugs for the treatment of rare genetic disorders. Report titled “Global Genetic Disorders Drugs Market to 2023 - A Rapidly Growing Treatment Landscape Driven by Targeted Complement System Inhibitors and Enzyme Replacement Therapies to Treat PNH and Lysosomal Storage Disease” helps the reader to gain more insights in the area of genetic disorders covering aspects such as Symptoms, Diagnosis, Treatment, Key products, clinical trials, company analysis and future forecast.


As rare genetic disorders are often debilitating or fatal, with low prevalence, sponsors are willing to pay for some of the most expensive treatments in the pharmaceutical industry. This contributes to high sales revenue, despite small patient groups. Orphan drugs are able to generate high revenue because of developmental incentives such as marketing exclusivity, which allows for longer periods before generics and biosimilars can enter the market. Furthermore, other incentives such as tax credits and accelerated approval lower the developmental costs faced by pharmaceutical companies, reducing the inherent financial risks involved and increasing the likelihood of recouping developmental costs from product sales.

The genetic disorders market has a strong presence of specialized companies that focus on the development of treatments for genetic disorders, including Alexion, Sanofi, Shire and Vertex. Treating genetic disorders can be a desirable prospect, as many genetic disorders are underserved – with only symptomatic treatments – allowing for high prices. Furthermore, a range of lucrative incentives such as orphan drug status are available for pharmaceutical companies to develop treatments for rare diseases, including extended periods of market exclusivity and tax credits. There is evidence of more companies moving into this therapy area, and a resultant diversification of market share.

Key Topics Covered in the Report:
Genetic disorders market research report
Genetic disorders treatment market
Genetic disorders medicine market
Genetic disorder cases worldwide
Genetic disorder Drugs Market
G Protein-Coupled Receptor Modulators Market
Metabolic Enzyme Mediators Market
Key Pipeline Products in Genetic Disorders Market
Clinical Trials in Genetic disorder Drugs Market
Soliris (eculizumab) Alexion Market
Orkambi (lumacaftor/ivacaftor) Vertex Market
Pulmozyme (dornase alfa) Roche Market
Duchenne Muscular Dystrophy Treatment Market
Lysosomal Storage Disease Treatment Market
Paroxysmal Nocturnal Hemoglobinuria Treatment Market

To know more about the publication, click on the link below:

Similar Reports:


Contact Us:                                                                                          
Ken Research
Ankur Gupta, Head Marketing & Communications
sales@kenresearch.com
0124-4230204